NCT02485938View on ClinicalTrials.gov

HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 7, 2016

Primary Completion Date

September 14, 2017

Study Completion Date

September 14, 2017

Conditions
Duchenne Muscular DystrophyCardiomyopathy
Interventions
DRUG

Allogeneic Cardiosphere-Derived Cells (CAP-1002)

Intracoronary delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002)

Trial Locations (3)

32611

University of Florida, Gainesville

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

90048

Cedars-Sinai Medical Center, Los Angeles

All Listed Sponsors
lead

Capricor Inc.

INDUSTRY

NCT02485938 - HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) | Biotech Hunter | Biotech Hunter